Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BOLT by emailGet an email when BOLT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BOLT, unsubscribe in one click. Privacy
📣 What BOLT Says Is Next
1Q 2027 · “Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, CA, August 11, 2026 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.”
Company press release, Aug 11, 2026 · SEC filing
fourth quarter · “Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, CA, Mar. 12, 2026 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.”
Company press release, Mar 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BOLT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BOLT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.